By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
Translating...
Content is automatically generated by Microsoft Azure Translator Text API. CGTN is not responsible for any of the translations.
TOP NEWS
Politics
07:00, 03-Mar-2025
Politics
11:22, 03-Mar-2025
Politics
03:24, 03-Mar-2025
RELATED STORIES
ShowBiz
12:29, 20-Jan-2025
Video
10:54, 26-Jan-2025
MORE FROM CGTN
Video
13:26, 03-Mar-2025
Economy
13:11, 03-Mar-2025
Economy
12:21, 03-Mar-2025
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
CGTN anchor Zheng Junfeng interviewed AstraZeneca CEO Pascal Soriot, delving into the company's extensive strategic layout in China's pharmaceutical industry. From focusing on the domestic market to becoming a core base for global manufacturing and innovation, AstraZeneca has strengthened its business in China through significant investments in Wuxi and Qingdao, as well as a strong emphasis on research and development, contributing to the advancement of global health and economic growth.